Day 109 on ruxolitinib · 952 days post-transplant · Oura ring · data through Jul 02 2026

After ruxolitinib

Nightly HRV nearly tripled.

+187%HRV, last 30 nights vs pre-treatment baseline

A consumer Oura ring tracked nightly autonomic recovery in one post-transplant patient. Heart rate variability rose from 9.0 to 26.0 ms. Resting heart rate fell. The step lines up with the day ruxolitinib started.

HRV (RMSSD)

9.0 → 26.0 ms

+187%

Parasympathetic, vagal, autonomic tone. Higher is better recovery.

Average sleeping HR

85 → 66 bpm

-22%

Lower resting heart rate means less cardiovascular strain.

Lowest nightly HR

77 → 57 bpm

-25%

The floor heart rate reaches overnight.

REM sleep

0.88 → 1.33 h

+52%

The sleep stage tied to memory and emotional recovery.

Last 30 nights (Jun 02 2026 to Jul 02 2026) vs the full pre-treatment baseline of 64 nights. Every figure is a live query.

The drug effect, night by night

Nightly HRV and resting heart rate. The dashed line marks ruxolitinib start.

Whole-period test: HRV +157% (p<0.001), all pre-ruxolitinib nights vs all post-ruxolitinib nights.

All reports

Core4
Full AnalysisHeart rate, HRV, sleep, activity, SpO2, and readiness trends across the full observation window.Biomarker TrendsComposite biomarker indices combining multiple Oura signals into research-use summary scores.Sleep AnalysisSleep architecture, staging distribution, efficiency, and circadian rhythm analysis.Weekly TrackerOne-page weekly tracker with watchpoints, week-over-week deltas, and clinician-style summary text.
Clinical6
Causal: RuxolitinibBayesian causal impact and interrupted time-series analysis of ruxolitinib response.GvHD PredictionHidden Markov and state-space models predicting GvHD flare probability from wearable signals.SpO2 & BOSSpO2 trend monitoring and bronchiolitis obliterans syndrome screening thresholds.Rux ForecastNear-term HRV and heart-rate recovery forecast from the current post-treatment trajectory.Research SynthesisTwo-hit autonomic recovery hypothesis with live KPIs, timeline, and statistical evidence.Treatment ReportPrimary clinical report covering all systems and both medicines for specialist review.
Advanced5
Advanced HRVFrequency-domain HRV, Poincare plots, DFA, sample entropy, and autonomic balance metrics.Digital TwinUnscented Kalman Filter digital twin tracking latent inflammatory and autonomic states.Foundation ModelChronos foundation model forecasting with prediction intervals and anomaly scoring.Anomaly DetectionMatrix Profile, Isolation Forest, and CUSUM anomaly detection across biometric channels.3D DashboardInteractive 3D scatter of sleep, HRV, and activity with treatment phase coloring.
Comparative8
Autonomic ComparisonHRV and resting HR recovery trajectories compared between post-HSCT and post-stroke patients.Treatment ResponseChangepoint detection and pre/post treatment response with Mann-Whitney U tests.Sleep ArchitectureSleep architecture, efficiency, and timing compared against clinical benchmarks.Activity-RecoveryActivity-recovery coupling analysis: does day N activity predict day N+1 recovery?Anomaly PatternsAnomaly fingerprinting and clustering: how bad days manifest differently.Breathing AnalysisRespiratory-rate trends, week-over-week shifts, and outlier nights against recent baseline.Temperature AnalysisTemperature deviation tracking, excursion alerts, and post-treatment change patterns.P2 ChangepointsPatient 2 changepoint scan of HRV, sleep, and recovery markers around key timeline events.
Statistical4
Piecewise ITSPiecewise ITS regression with AR(1) errors: two-intervention model with date sensitivity analysis.Sequential CISequential Bayesian CausalImpact isolating Jakavi and beta-blocker effects in separate runs.Placebo TestsFalsification tests at 20 random pre-treatment dates to calibrate false positive rates.Tau-U EffectsTau-U and NAP effect sizes for single-case experimental design with baseline trend correction.
Individual2
P2 DashboardPost-stroke patient P2: HRV, HR, sleep, and activity dashboard.P3 DashboardHealthy control P3: baseline HRV, HR, sleep, and activity reference.
Context2
AboutMethodology, limitations, and honest assessment of what this system can and cannot do.Next StepsPlanned analyses, validation targets, and next steps for the digital twin platform.